Eureka Therapeutics Inc. has entered into a license agreement with the National Cancer Institute (NCI) to develop and commercialize a novel antibody targeting mesothelin (MSLN) in combination with Eureka's proprietary Artemis T-cell receptor platform.

A new experimental drug, QN-302, has shown high antiproliferative activity in pancreatic cancer cells and antitumor activity in experimental pancreatic cancer models.

Vesigen Therapeutics Inc. has been awarded a grant by the Friedreich’s Ataxia Research Alliance (FARA) to develop a targeted genome editing therapeutic strategy for Friedreich’s ataxia.

Abeona Therapeutics Inc. has announced three investigational preclinical gene therapy product candidates from its ophthalmology program. The new AAV-based therapies use novel AAV capsids from Abeona's in-licensed AIM capsid library. Abeona intends to submit its first pre-IND application meeting request this month.

High levels of bilirubin exacerbated damage to neurons in the brain caused by a stroke by binding to the TRPM2 channel, which helped regulate cell death among other processes. The research, led by Shanghai Jiao Tong University School of Medicine and the University of Toronto and published March 14, 2023, in Neuron, showed that blocking the binding site for bilirubin in a mouse model led to improvements in neurotoxicity suggesting some potential for the development of new stroke therapeutics.

Switch Therapeutics Inc. has announced its launch following US$52 million of financing. The company was founded on the premise of a new type of RNA medicine that integrates nucleic acid nanotechnology and RNA interference (RNAi) science.